The role of oxidatively modified lipoproteins in lipid nephropathy

Contributions to Nephrology

Volumn 120, Issue , 1997, Pages 160-175

  Gröne, Hermann Josef ^a   Walli, Autar K ^b   Gröne, Elisabeth F ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYTOKINE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE;

CELL DIVISION; EXTRACELLULAR MATRIX; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; REVIEW;

ANTIOXIDANTS; CELL DIVISION; CYTOKINES; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; LIPOPROTEINS, LDL; NEPHRITIS, INTERSTITIAL; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 0030623995     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (97)

1. Moorhead JF, Chan MK, El Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 1982;ii:309-1310.
2. Gröne EF, Walli AK, Gröne HJ, Miller B, Seidel D: The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 1994;107:1-13.
3. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 1988;33:917-924.
4. Alexander RW: Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response - A new perspective. Hypertension 1995;25:155-161.
5. Haberland ME, Fong D, Cheng L: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988;241:215-218.
6. Boyd HC, Gown AM, Wolfbauer G, Chait A: Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 1989;135:815-825.
7. Rosenfeld ME, Palinski S, Ylä-Herttuala S, Butler S, Witztum JL: Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990;10:336-349.
8. Rosenfeld ME, Khoo JC, Miller E, Parthasarathy S, Palinski W, Witztum JL: Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest 1991;87:90-99.
9. Jürgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP: Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein (a). Arterioscler Thromb 1993;13:1689-1699.
10. Salmon S, Maziere C, Theron L, Beucler I, Ayrault-Jarrier M, Goldstein S, Polonovski J: Immunological detection of low-density lipoproteins modified by malondialdehyde in vitro or in vivo. Biochim Biophys Acta 1987;920:215-220.
11. Rubin E, Faber JL (eds): Pathology. Philadelphia, Lipincott, 1994, pp 16-22.
12. Esterbauer H, Rotheneder M, Striegl G, Waeg G, Ashy A, Sattler W, Jürgens G: Vitamin-E and other lipophilic antioxidants protect LDL against oxidation. Fat Sci Technol 1989;8:316-324.
13. Thomas CE, Jackson RL, Ohlweiler DF, Ku G: Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res 1994;35:417-127.
14. Esterbauer H, Gebicki J, Puhl H, Jürgens G: The role of lipid-peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992;13:341-390.
15. Lenz ML, Hughes H, Mitchell JR, Via DP, Guyton JR, Taylor AA, Gotto AM Jr, Smith CV: Lipid hydroperoxy and hydroxy derivatives in copper-catalyzed oxidation of low density lipoprotein. J Lipid Res 1990;31:1043-1050.
16. Thomas CE, Jackson RL: Lipid hydroperoxide involvement in copper-dependent and independent oxidation of low-density lipoproteins. J Pharmacol Exp Ther 1991;256:1182-1188.
17. Clare K, Hardwick SJ, Carpenter KLH, Weeratunge N, Mitchinson MJ: Toxicity of oxysterols to human monocyte-macrophages. Atherosclerosis 1995;118:67-75.
18. Carpenter KLH, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ: Lipids and oxidized lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta 1995;1256:141-150.
19. Javitt NB: 26-Hydroxycholesterol: Synthesis, metabolism and biological activities. J Lipid Res 1990;31:1527-1533.
20. Hazell LJ, Stocker R: Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J 1993;290:165-172.
21. Malle E, Hazell L, Stocker R, Sattler W, Esterbauer H, Waeg G: Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler Thomb Vasc Biol 1995;15:982-989.
22. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996;97:1535-1544.
23. 22a Malle E, Woenckhaus C, Waeg G, Esterbauer H, Gröne EF, Gröne H-J: Immunological evidence for hypochlorile-modified proteins in human kidney. Am J Pathol, in press 1997.
24. Daugherty A, Dunn JL, Rateri DL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444.
25. Savenkova MI, Mueller DM, Heinecke JW: Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 1994;269:20394-20400.
26. Scaccini C, Nardini M, D'Aquino M, Gentili V, Di Felice M, Tomassi G: Effect of dietary oils on lipid peroxidation and on antioxidant parameters of rat plasma and lipoprotein fractions. J Lipid Res 1992;33:627-633.
27. Drake TA, Hannani K, Fei H, Lavi S, Berliner JA: Minimally oxidized low-density-lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 1991;138:601-607.
28. Parthasarathy S, Fong LG, Otero D, Steinberg D: Recognition of solubilized apoproteins from delipidated, oxidized low-density lipoprotein (LDL) by the acetyl-LDL receptor. Proc Natl Acad Sci USA 1987;84:537-540.
29. Arai H, Kita T, Yokode M, Narumiya S, Kawai C: Multiple receptors for modified low-density lipoproteins in mouse peritoneal-macrophages: Different uptake mechanisms for acetylated and oxidized low-density lipoproteins. Biochem Biophys Res Commun 1989;159:1375-1382.
30. Sparrow CP, Parthasarathy S. Steinberg D: A macrophage receptor that recognized oxidized low-density lipoprotein but not acetylated low-density lipoprotein. J Biol Chem 1989;264:2599-2604.
31. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigami M, Miyagama JI, Kameda-Takemura K, Kurata Y, Matsuzawa Y: Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 1995;96:1859-1865.
32. Lopes-Virella MF, Virella G: Atherosclerosis and autoimmunity. Clin Immunol Immunopathol 1994;73:155-167.
33. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low-density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-2998.
34. Malden LT, Chait A, Raines EW, Ross R: The influence of oxidatively modified low-density lipoproteins on expression of platelet-derived growth-factor by human monocyte-derived macrophages. J Biol Chem 1991;266:3901-3907.
35. Frostegord J, Wu R, Haegerstrand A, Patarroyo M, Lefvert AK, Nilsson J: Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis 1993;103:213-219.
36. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-1874.
37. Tanner FC, Noll G, Boulanger CM, Lüscher TF: Oxidized low-density lipoproteins inhibit relaxations of porcine coronary-arteries - Role of scavenger receptor and endothelium-derived nitric oxide. Circulation 1991;83:2012-2020.
38. Galle J, Öchslen M, Schollmeyer P, Wanner C: Oxidized lipoproteins inhibit endothelium-dependent vasodilation: Effects of pressure and high-density lipoprotein. Hypertension 1994;23:556-564.
39. Parthasarathy S, Quinn MT, Schwenke DC, Carew TE, Steinberg D: Oxidative modification of beta-very low-density lipoprotein: Potential role in monocyte recruitment and foam cell-formation. Arteriosclerosis 1989;9:398-404.
40. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ: Induction of endothelial-cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-257.
41. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM: Monocyte transmigration induced by modification of low-density-lipoprotein in cocultures of human aortic-wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high-density-lipoprotein. J Clin Invest 1991;88:2039-2046.
42. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM: Minimally modified low-density-lipoprotein induces monocyte chemotactic protein-1 in human endothelial-cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-5138.
43. Fong LG, Fong TAT, Cooper AD: Inhibition of lipopolysaccharide-induced interleukin-1β mRNA expression in mouse macrophages by oxidized low density lipoprotein. J Lipid Res 1991;32:1899-1910.
44. Hamilton TA, Ma G, Chisolm GM: Oxidized low-density-lipoprotein suppresses the expression of tumor necrosis factor-α mRNA in stimulated murine peritoneal macrophages. J Immunol 1990;144:2343-2350.
45. Hamilton TA, Major JA, Chisolm GM: The effects of oxidized low density lipoproteins on inducible mouse macrophage gene expression are gene and stimulus dependent. J Clin Invest 1995;95:2020-2027.
46. Schreck R, Rieber P, Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 1991;10:2247-2258.
47. Staal FJT, Roederer TM, Herzenberg LA: Intracellular thiols regulate activation of nuclear factor κB and transcription of human- immunodeficiency-virus. Proc Natl Acad Sci USA 1990;87:9943-9947.
48. Shackelford RE, Misra UK, Forine-Casteel K, Thai SF, Pizzo SV, Adams DO: Oxidized low-density lipoprotein suppresses activation of NFκB in macrophages via a pertussis toxin-sensitive signalling mechanism. J Biol Chem 1995;270:3475-3478.
49. 2 subunit expression by oxidized low-density lipoprotein. J Clin Invest 1995;95:1457-1463.
50. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D: Interactions of LDL and modified LDL with mesangial cella and matrix. Kidney Int 1992;41:1161-1169.
51. Wheeler DC, Chana RS: Interactions between lipoproteins, glomerular cells and matrix. Miner Electrolyte Metab 1993;19:149-164.
52. Parthasarathy S, Steinberg D, Witztum JL: The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med 1992;43:219-226.
53. Chandrakasan G: Stimulation of collagen synthesis in fibroblast cultures by superoxide. Cell Mol Biol 1991;37:751-755.
54. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM: Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth-muscle cells. J Clin Invest 1995;96:2322-2330.
55. Guyton JR, Black BL, Seidel CL: Focal toxicity of oxysterols in vascular smooth-muscle cell-culture: A model of the atherosclerotic core region. Am J Pathol 1990;137:425-434.
56. Smith LL, Johnson BH: Biological activities of oxysterols. Free Radic Biol Med 1989;7:285-332.
57. Tipton CL, Leung PC, Johnson JS, Brooks RJ, Beitz DC: Cholesterol hydroperoxides inhibit calmodulin and suppress atherogenesis in rabbits. Biochem Biophys Res Commun 1987;146:1166-1172.
58. Kandutsch AA, Chen HW, Shown EP: Binding of 25-hydroxycholesterol and cholesterol to different cytoplasmic proteins. Proc Natl Acad Sci USA 1977;74:2500-2503.
59. Coffey MD, Cole RA, Colles SM, Chisolm GM: In vitro cell injury by oxidized low-density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid, and peroxyl radicals. J Clin Invest 1995;96:1866-1873.
60. Kosugi K, Morel DW, Dicorleto PE, Chrisolm GM: Toxicity of oxidized low-density lipoprotein to cultured fibroblasts is selective for S phase of the cell cycle. Cell Physiol 1987;130:311-320.
61. Parthasarathy S, Rankin SM: Role of oxidized low-density lipoprotein in atherogenesis. Prog Lipid Res 1992;31:127-143.
62. Keane WF: Lipids and the kidney. Kidney Int 1994;46:910-920.
63. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T: Sensitive detection of oxidatively modified low-density lipoprotein using a monoclonal antibody. J Lipid Res 1996;37:45-53.
64. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G: Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-876.
65. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS: Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994;58:663-669.
66. Wang C, Salahudeen AK, McClain M, Whitehead J: Lipid peroxidation accompanies cyclosporine nephrotoxicity: Effects of vitamin E. Kidney Int 1995;47:927-934.
67. Sutherland WHF, Walker RJ, Ball MJ, Stapley SA, Robertson MC: Oxidation of low-density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995;48:227-236.
68. Hörkkö S, Huttunen K, Korhonen T, Kesäniemi YA: Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int 1994;45:561-570.
69. Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP: Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 1993;43:1243-1250.
70. Neugarten J, Ghossein C, Silbiger S: Estradiol inhibits cell-mediated oxidation of low-density lipoprotein. Lab Clin Med 1995;126:385-391.
71. Wheeler DC, Chana RS, Topley N, Petersen MM, Davies M, Williams JD: Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 1994;45:1628-1636.
72. Gröne EF, Abboud HE, Höhne M, Walli AK, Gröne HJ, Stüker D, Robenek H, Wieland E, Seidel D: Actions of lipoproteins in cultured human mesangial cells: Modulation by mitogenic vasoconstrictors. Am J Physiol 1992;263:F686-F696.
73. Gröne HJ, Hohbach J, Gröne EF: Modulation of glomerulosclerosis and interstitital fibrosis by native and modified lipoprotein. Kidney Int 1996;49(suppl 54):18-22.
74. Walli AK, Gröne HF, Gröne E, Miller B, Seidel D: Receptor-mediated uptake and action of lipoproteins in cultured human mesangial cells and their modulation by mitogenic vasoconstrictors. Circulation 1992;86(suppl):544.
75. Van Goor H, Fidler V, Weening JJ, Grond J: Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation. Evidence for involvement of macrophages and lipids. Lab Invest 1991;64:754-765.
76. Boud L, Fouqueray B, Philippe C, Ardaillou R: Reactive oxygen species as glomerular autacoids. J Am Soc Nephrol 1992;2:S132-S138.
77. Hiramatsu K, Rosen H, Heinecke JW, Wolfbauer G, Chait A: Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis 1987;7:55-60.
78. Neale TJ, Ojha PP, Exner M, Poczewski H, Rüger B, Witztum JL, Davis P, Kerjaschki D: Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest 1994;94:1577-1584.
79. Naito M, Kodama T, Matsuoto A, Doi T, Takahashi K: Tissue distribution, intracellular localization and in vitro expression of bovine macrophage scavenger receptors. Am J Pathol 1991;139:1411-1423.
80. Takemura T, Yoshioka K, Aya N, Murokami K, Matumoto A, Itakure H, Kodama F, Suzuki H, Maki S: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney-diseases. Kidney Int 1993;43:918-927.
81. Lee HS, Koh HI: Visualization of binding and uptake of oxidized low density lipoproteins by cultured mesangial cells. Lab Invest 1994;71:200-208.
82. Neugarten J, Schlondorff D: Lipoprotein interactions with glomerular cells and matrix; in Keane WF, Stein JH (eds): Contemporary Issues in Nephrology. Lipids and Renal Disease. New York, Churchill-Livingstone 1991, vol 24: p 173.
83. Coritsidis G, Rific V, Gupta S, Rie J, Shan Z, Neugarten J, Schlondorff D: Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 1991;39:858-866.
84. Suzaki K, Kobori S, Ide M, Sasahara T, Sakai M, Toyonaga T, Shinohara M, Miyazaki A, Horiuchi S, Takeda H, Shichiri M: Acetyl-low density lipoprotein receptors on rat mesangial cells. Atherosclerosis 1993;101:177-184.
85. Sachinidis A, Locher R, Velter W: Generation of intracellular signals by low density lipoprotein is independent of the classical LDL receptor. Am J Hypertens 1991;4:274-279.
86. Massaeli H, Pierce GN: Involvement of lipoproteins, free-radicals, and calcium in cardiovascular-disease processes. Cardiovasc Res 1995;29:597-603.
87. Liu K, Massaeli H, Pierce GN: The action of oxidized low-density- lipoprotein on calcium transients in isolated rabbit cardiomyocytes. J Biol Chem 1993;268:4145-4151.
88. Bank N, Aynedjian HS: Role of thromboxane in impaired renal vasodilatation response to acetylcholine in hypercholesterolemic rats. J Clin Invest 1992;89:1636-1642.
89. Chin JH, Azhar S, Hoffman BB: Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992;89:10-18.
90. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol - Modification of low-density lipoprotein that increases atherogenicity. N Engl J Med 1989;320:915-924.
91. Parthasarathy S, Rankin SM: Role of oxidized low density lipoprotein in atherogenesis. Prog Lipid Res 1992;31:127-143.
92. Mackensen-Haen S, Bader K, Grund KE, Bohle A: Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin Nephrol 1981;15:167-171.
93. Ong ACM, Jowett TP, Moorhead JF, Owen JS: Human high-density-lipoproteins stimulate endothelin-1 release by cultured human renal proximal tubular cells. Kidney Int 1994;46:1315-1321.
94. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Effects of reduced renal mass on tissue-lipids and renal injury in hyperlipidemic rats. Kidney Int 1989;35:40-47.
95. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990;37:880-891.
96. Modi KS, Schreiner GF, Purkerson ML, Klahr S: Effects of probucol in renal-function and structure in rats with subtotal kidney ablation. J Lab Clin Med 1992;120:310-317.
97. Hattori M, Ito K, Kawaguchi H, Yamaguchi Y: Probucol reduces renal injury in the Exhc rat. Nephron 1994;67:459-468.